Stay updated on Pembrolizumab for Rare Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Rare Tumors Clinical Trial page.

Latest updates to the Pembrolizumab for Rare Tumors Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoChange DetectedAdded a Texas location under Locations and updated the revision to v3.3.3. Removed the HHS Vulnerability Disclosure and the Texas Locations entry from the prior revision (v3.3.2).SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check41 days agoChange DetectedAdded note that publications are automatically filled from PubMed and included Revision: v3.3.2. Removed the older text stating PubMed publications are automatically created by ClinicalTrials.gov and may not be about the study.SummaryDifference0.1%

- Check48 days agoChange DetectedThe funding-status notice about potential delays due to a lapse in government funding has been removed. All study details and eligibility information remain unchanged.SummaryDifference0.3%

- Check63 days agoChange DetectedA new publication entry was added to Publications: Chahla B, Stephen B, Song J, Balderrama-Brondani V, Yaylaci F, Campbell MT, Naing A, Habra MA; Phase 2 Study of Monotherapy with Pembrolizumab for Advanced Adrenocortical Carcinoma, J Immunother Precis Oncol. 2025 Oct 6;8(4):242-248; doi: 10.36401/JIPO-25-6; eCollection 2025 Nov.SummaryDifference0.4%

- Check91 days agoChange DetectedIntroducing version v3.2.0 and a government-operating-status notice; removing the older v3.1.0 reference.SummaryDifference2%

- Check98 days agoChange DetectedThe page update adds the new version tag v3.1.0 and removes the old v3.0.2 tag, signaling a software version upgrade.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab for Rare Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Rare Tumors Clinical Trial page.